Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.

导出 LinkOut

翻译打印收藏纠错

作者： Behnam,Amani ^[1] ; Bahman,Amani ^[2] ; Sara,Zareei ^[3] ; Mahsa,Zareei ^[4]

作者单位： Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. ^[1] Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran. ^[2] Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. ^[3] Department of Health Services Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. ^[4]

关键词 2019 novel coronavirus infection 2019-nCoV infection arbidol coronavirus novel coronavirus umifenovir

主题词抗病毒药(Antiviral Agents);人类(Humans);吲哚类(Indoles)

DOI 10.1002/iid3.502

PMID 34347937

发布时间 2024-08-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Immunity, inflammation and disease

2021年9卷4期

1197-1208页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.

Immunity, inflammation and disease

相似文献

Immunity, inflammation and disease

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.

Immunity, inflammation and disease

相似文献

Immunity, inflammation and disease

相关期刊

检索历史清除